Knight Therapeutics Inc.

TSX:GUD.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$11.56 +0.75%

+$0.07 today

Market cap
$1.14B
Beta
0.07
P/E (TTM)
164.6
EPS (TTM)
$0.06
52W Low $5.66High $9.59

Volume 0.04M

Average 0.10M

GUD.TO Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Knight Therapeutics Inc.TSX: GUD.TO

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 36.7%

Gross margin was 36.7% in Q1 FY2026, down 2.9 pp from a year earlier. On a trailing-twelve-month basis it was 37.3%, down 7.6 pp year over year. Over 3 fiscal years it narrowed by 13.5 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
36.7%-1.6 pp QoQ
Last fiscal yearDec 2025
33.5%-13.5 pp YoY
LTMMar 2026
37.3%-7.6 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-2.9 pp——
1 year-13.5 pp——
3 years-13.5 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
33.5%
Year-over-year change
-13.5pp

Gross Margin vs competitors

How GUD.TO compares with its peers on the latest reported figures

  • GUD.TO's LTM Mar 2026 gross margin of 37.3% is the 5th highest of the 8 companies compared; the peer median is 50.9%.
  • Its year-over-year change of -7.6 pp is the 5th highest of 8, against a peer median of -6.1 pp.
  • Over three fiscal years its change of -13.5 pp compares with a peer median of -3.2 pp.
GUD.TO Competitors Peer median
Gross Margin for GUD.TO and competitors
Company Period LTM level YoY 3-year change
VHI.TOVitalhub Corp.LTM Mar 202674.8% -6.1 pp-12.2 pp
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 202674.5% +2.6 pp-14.9 pp
KSI.TOKneat.com, Inc.LTM Mar 202660.1% -15.0 pp-6.9 pp
TSND.TOTerrAscend Corp.LTM Mar 202650.9% -0.7 pp+0.4 pp
GUD.TOKnight Therapeutics Inc.LTM Mar 202637.3% -7.6 pp-13.5 pp
ACB.TOAurora Cannabis Inc.LTM Mar 202631.5% -23.2 pp+32.8 pp
WEED.TOCanopy Growth CorporationLTM Mar 202623.6% -5.9 pp+54.0 pp
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026-3.1% -35.8 pp—
Peer median (excluding GUD.TO) 50.9%-6.1 pp-3.2 pp

Competitors are the stored peer set for GUD.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue243.48M293.56M328.2M371.3M450.09M
Cost of Revenue128.07M155.5M175.55M196.9M299.35M
Gross Profit115.41M138.06M152.65M174.41M150.74M
Gross Margin47.4%47.0%46.5%47.0%33.5%
Research & Development12.69M14.76M17.55M23.3M28.98M
Selling, General & Admin74.38M88.62M83.69M99.35M123.96M
Operating Expenses128.24M155.12M155.54M167.01M152.94M
Depreciation & Amortization47.92M62.62M50.4M53.11M56.57M
EBITDA42.59M25.26M40.9M64.38M54.37M
EBITDA Margin17.5%8.6%12.5%17.3%12.1%
Operating Income(5.32M)(2.4M)(2.89M)7.4M(2.2M)
Operating Margin-2.2%-0.8%-0.9%2.0%-0.5%
Interest Income7.38M10.63M12.58M10.41M6.21M
Interest Expense3.62M6.6M12.49M9.22M10.42M
Other Income / Expenses19.52M(2.92M)(19.1M)(5.35M)(4.5M)
Income Before Tax6.69M(43.96M)(21.99M)2.05M(6.7M)
Pre-Tax Margin2.7%-15.0%-6.7%0.6%-1.5%
Income Tax Expense(8.99M)(14.07M)(5.15M)(2.28M)(1.33M)
Net Income15.68M(29.89M)(16.84M)4.33M(5.37M)
Net Margin6.4%-10.2%-5.1%1.2%-1.2%
EPS (Basic)0.13(0.26)(0.16)0.04(0.05)
EPS (Diluted)0.13(0.26)(0.16)0.04(0.05)
Weighted Avg Shares124.48M114.89M107.47M101.04M99.57M
Weighted Avg Shares (Diluted)124.52M114.89M107.47M101.44M99.57M

Knight Therapeutics Inc.

TSX:GUD.TO

Intrinsic Alpha fair value

Locked

Current Price

$11.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.